Realfiction Holding AB: Pfizer Inc. initiates mixed reality pilot project with Realfiction order
This morning Realfiction Holding AB (“Realfiction”) has received an order from our South African reseller, for the US based pharmaceutical company Pfizer Inc., for a large in-store project in South Africa.
The project which gives Realfiction a revenue of approximately 600.000 SEK will include rollout in more than 60 pharma stores across South Africa. This makes the project the largest of its kind on the African continent and is planned for implementation in October 2017. The project in South Africa has been selected by the global pharmaceutical company as a pilot test, and results will be evaluated by US headquarters accordingly.
“It will be a pleasure to work with our local partners in South Africa on this project, and we are excited about this new landmark in the region,” says Clas Dyrholm, CEO of Realfiction.
Sedermera Fondkommission is the company’s Certified Adviser.
For more information about Realfiction, please contact:
Founder & CEO
Mobile: +45 2522 3281
This information is information that Realfiction Holding AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, on August 3rd, 2017.
Founded in Denmark in 2008, Realfiction is a market innovator within mixed-reality solutions, a market estimated to reach USD 80 billion in 2025. Realfiction’s first product, Dreamoc, has since its launch sold over 10.000 units, and the company is now launching its new patent-pending technology DeepFrame, a series of ground-breaking large format mixed-reality screens. DeepFrame offers a wealth of new applications for companies across industries such as entertainment, manufacturing and retail, as well as a broad range of future consumer products.